CN115137771B - 用于治疗缺血性心脑血管疾病的消栓片及其制备方法 - Google Patents
用于治疗缺血性心脑血管疾病的消栓片及其制备方法 Download PDFInfo
- Publication number
- CN115137771B CN115137771B CN202210668785.4A CN202210668785A CN115137771B CN 115137771 B CN115137771 B CN 115137771B CN 202210668785 A CN202210668785 A CN 202210668785A CN 115137771 B CN115137771 B CN 115137771B
- Authority
- CN
- China
- Prior art keywords
- thrombolytic
- powder
- earthworm
- tablet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002537 thrombolytic effect Effects 0.000 title claims abstract description 133
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 128
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 48
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 42
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 42
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 129
- 239000000843 powder Substances 0.000 claims abstract description 83
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000008188 pellet Substances 0.000 claims abstract description 56
- 238000002156 mixing Methods 0.000 claims abstract description 46
- 238000000605 extraction Methods 0.000 claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 42
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 39
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 39
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 39
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 39
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 39
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 22
- 241001061264 Astragalus Species 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- 210000004233 talus Anatomy 0.000 claims abstract description 17
- 238000003825 pressing Methods 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims description 41
- 238000001035 drying Methods 0.000 claims description 32
- 239000011248 coating agent Substances 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 29
- 238000001914 filtration Methods 0.000 claims description 25
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 20
- 241000125175 Angelica Species 0.000 claims description 19
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- 229940107666 astragalus root Drugs 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000011812 mixed powder Substances 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 241000212322 Levisticum officinale Species 0.000 claims description 9
- 239000001645 levisticum officinale Substances 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 239000002702 enteric coating Substances 0.000 claims description 7
- 238000009505 enteric coating Methods 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000004677 Nylon Substances 0.000 claims description 5
- 229920003081 Povidone K 30 Polymers 0.000 claims description 5
- 229920001778 nylon Polymers 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000005057 refrigeration Methods 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 3
- 241000213006 Angelica dahurica Species 0.000 claims 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 241001106477 Paeoniaceae Species 0.000 abstract description 34
- 239000002994 raw material Substances 0.000 abstract description 34
- 239000003814 drug Substances 0.000 abstract description 27
- 239000000463 material Substances 0.000 abstract description 26
- 108010070324 lumbrokinase Proteins 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 13
- 241000382455 Angelica sinensis Species 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000002040 relaxant effect Effects 0.000 abstract description 4
- 210000003462 vein Anatomy 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 68
- 239000000243 solution Substances 0.000 description 52
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000013641 positive control Substances 0.000 description 26
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 20
- 241000243684 Lumbricus Species 0.000 description 15
- 239000006187 pill Substances 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000001276 controlling effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 241001233061 earthworms Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229960003943 hypromellose Drugs 0.000 description 8
- 238000003809 water extraction Methods 0.000 description 8
- 210000001168 carotid artery common Anatomy 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010019468 Hemiplegia Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 5
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 5
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 241000628997 Flos Species 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000008561 buyang huanwu Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003073 embolic effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | 红细胞-蛋白任氏液黏度 |
假手术对照组 | 4.33±0.7 |
空白组 | 6.11±0.4 |
消栓肠溶胶囊组 | 4.59±0.5 |
消栓肠溶胶囊I组 | 5.17±1.3 |
消栓胶囊组 | 5.66±1.2 |
消栓片组 | 4.12±0.8 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210668785.4A CN115137771B (zh) | 2022-06-14 | 2022-06-14 | 用于治疗缺血性心脑血管疾病的消栓片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210668785.4A CN115137771B (zh) | 2022-06-14 | 2022-06-14 | 用于治疗缺血性心脑血管疾病的消栓片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115137771A CN115137771A (zh) | 2022-10-04 |
CN115137771B true CN115137771B (zh) | 2024-05-03 |
Family
ID=83409273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210668785.4A Active CN115137771B (zh) | 2022-06-14 | 2022-06-14 | 用于治疗缺血性心脑血管疾病的消栓片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115137771B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911251A (zh) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | 一种以鲜地龙提取物为活性成分的中药肠溶口服制剂及其制备方法 |
CN105250427A (zh) * | 2015-11-08 | 2016-01-20 | 长沙佰顺生物科技有限公司 | 一种治疗心脏疾病的药物组合物 |
-
2022
- 2022-06-14 CN CN202210668785.4A patent/CN115137771B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911251A (zh) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | 一种以鲜地龙提取物为活性成分的中药肠溶口服制剂及其制备方法 |
CN105250427A (zh) * | 2015-11-08 | 2016-01-20 | 长沙佰顺生物科技有限公司 | 一种治疗心脏疾病的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN115137771A (zh) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108355047A (zh) | 一种百合地黄汤固体制剂的制备工艺 | |
CN115137771B (zh) | 用于治疗缺血性心脑血管疾病的消栓片及其制备方法 | |
CN103550164B (zh) | 一种益气健脾的归脾丸(微丸) | |
CN111366680B (zh) | 一种物质含量测定方法及其应用 | |
CN1943707B (zh) | 一种用于抗衰老的中药组合物及其制备方法 | |
CN102085257A (zh) | 一种桂枝茯苓微丸的制备方法 | |
CN115531463B (zh) | 一种治疗高脂血症的中药 | |
CN103800690A (zh) | 一种龙血树叶、石斛药物组合物及其制备方法、制剂和应用 | |
CN1857385B (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN101439134A (zh) | 一种中药制剂的制备方法 | |
CN102309538B (zh) | 一种复方地龙提取物及其制备方法和其组合物 | |
CN102166241A (zh) | 一种三七总皂苷肠溶微囊剂 | |
CN111588763B (zh) | 血栓通脉药物、制备方法及含量测定方法 | |
CN101632726B (zh) | 一种中药组合物在制备治疗血管微栓塞的药物中的应用 | |
CN107411050A (zh) | 灵芝孢子粉提取物的提取方法及其应用 | |
CN111228419A (zh) | 一种脉络舒通微丸制剂及其制备方法 | |
CN105561097B (zh) | 一种治疗结核病的中药组合物及其制备方法 | |
CN108653401A (zh) | 一种治疗溃疡性结肠炎的复方药物制剂及其制备方法 | |
CN113546049B (zh) | 一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂 | |
CN100496465C (zh) | 治疗妇科疾病的中药制剂及其制备方法 | |
CN110742864A (zh) | 一种改性中药浸膏粉的制备方法 | |
CN113559070B (zh) | 一种适用于宠物咳嗽的药物制备方法 | |
CN115429851B (zh) | 一种鹿晶益气生血丸及其制备工艺和应用 | |
CN113995791B (zh) | 一种能益气养血、预防和治疗贫血的平卧菊三七复方药物及其制备方法和应用 | |
CN107970341A (zh) | 一种三七接骨凝胶膏剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 541000 The third floor of No. 8 standard factory building, Yangtang Industrial Park, Lingui Town, Lingui District, Guilin City, Guangxi Zhuang Autonomous Region Applicant after: Jiuhua Huayuan Pharmaceutical (Guilin) Co.,Ltd. Address before: 541000 the third floor of standard plant No.2, Yangtang Industrial Park, Lingui Town, Lingui District, Guilin City, Guangxi Zhuang Autonomous Region Applicant before: Guangxi chunzhengtang Pharmaceutical Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant |